Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Sanofi Data Shows Vaccine Candidate Effective In Dengue Caused By 3 Virus Types

French drugmaker Sanofi's (SNY: Quote, SNYNF) vaccines division Sanofi Pasteur late Monday announced the online publication of clinical study results showing that its vaccine candidate protects against dengue fever caused by three dengue virus types.

The results of the world's first efficacy study confirm the safety profile of the dengue vaccine candidate, the firm said. The study results have been published in The Lancet.

Dengue is a mosquito-borne disease caused by four dengue virus serotypes. It is a threat to nearly 3 billion people, especially in some countries of Latin America and Asia.

The full analysis of vaccine efficacy against each serotype, reflecting real-life conditions, showed vaccine efficacy to be 61.2 percent against dengue virus type 1, 81.9 percent against type 3 and 90 percent against type 4.

One of the dengue virus types (serotype 2) eluded the vaccine. Sanofi said analyses are in progress to understand the lack of protection for serotype 2 in the particular epidemiological context of Thailand.

The study was conducted in 4,002 children aged 4 to 11 years, in partnership with the Mahidol University under the patronage of the Thai Ministry of Public Health.

Sanofi Pasteur's dengue vaccine candidate is a live, attenuated vaccine. The vaccination schedule is 3 doses given 6 months apart at 0, 6 and 12 months.

Dr. Scott Halstead, International Vaccine Institute, Seoul, Republic of Korea, said, ''The complexity of dengue virus infection has hampered vaccine research for decades. This is the first time in 50 years of dengue research that I have seen a vaccine that protected a large group of children from clinical disease caused by dengue viruses. Best yet, the vaccine met the highest safety expectations."

Large-scale phase III clinical studies of the dengue vaccine candidate are underway with 31,000 children and adolescents in 10 countries in Asia and Latin 2/3 America. These studies are expected to generate additional data in a broader population and in several epidemiological settings.

Sanofi closed in Paris on Monday lower by 0.65 percent at 65.72 euros on 2.01 million shares.

Register
To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.